Blood Cancer Talks

Episode 37. ASH 2023 Myeloma Recap with Dr. Ben Derman

Dec 27, 2023

Dr. Ben Derman, expert in myeloma, discusses key abstracts at ASH23 including new diagnostic criteria for light chain MGUS, trials comparing Dara-VRD vs VRD and Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma, a phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma, long-term follow-up data on salvage transplant in myeloma, overall survival results of KarMMa-3 trial, and a trial comparing Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients. The podcast also covers the revised definition of light chain MGUS, the use of Dara in maintenance therapy, Dara Venetoclaxedex in relapse refractory myeloma, survival results of the Karma 3 trials, and comparing CAR-T therapies.

01:01:40

Creator website

Episode guests

Ben Derman

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Revised diagnostic criteria for light chain MGUS aim to reduce unnecessary referrals and worry.

The addition of daratumumab to induction therapy for newly diagnosed myeloma improves minimal residual disease negativity and progression-free survival.

A second autologous stem cell transplant may not provide significant benefits compared to continuous len-dex therapy for relapsed myeloma patients.

Deep dives

Revised definition of light chain MGUS

The ISTOP MM study provided a revised definition of light chain MGUS, based on data from 42,000 individuals in Iceland. They found that the new upper limit of the serum free light chain ratio for patients under 70 is around 2.16, and for patients age 70 and older it is around 2.59. These updated criteria help identify patients who actually have light chain MGUS, reducing unnecessary referrals and worry.

Introduction

2min

Revised Definition of Light Chain MGUS and Implications for Clinical Practice

4min

DARA Maintenance and Deepening MRD Negativity

31min

Dara Venetoclaxedex in Relapse Refractory Myeloma

12min

Survival Results of the Karma 3 Trials

10min

Comparing CAR-T Therapies and Discussing Patient Populations

2min

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode:

First, we will focus on a few abstracts in precursor states, MGUS.

1. New diagnostic criteria for light chain MGUS (IStopMM):

https://ash.confex.com/ash/2023/webprogram/Paper188547.html

https://ash.confex.com/ash/2023/webprogram/Paper182661.html

2. PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma:

https://ash.confex.com/ash/2023/webprogram/Paper191911.html

3. ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma:

https://ash.confex.com/ash/2023/webprogram/Paper177546.html

4. Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma:

https://ash.confex.com/ash/2023/webprogram/Paper180766.html

5. GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma)

https://ash.confex.com/ash/2023/webprogram/Paper178835.html